Publications by authors named "R Sweis"
THE OPTIMAL DURATION OF pH-MONITORING: TESTING THE VALIDITY OF LYON 2.0 RECOMMENDATIONS FOR WIRELESS pH MEASUREMENT.
Clin Gastroenterol Hepatol
December 2024
Background And Aims: The Lyon 2.0 consensus recommends 96-hr wireless pH studies for GERD diagnosis; however, the optimal length of pH-measurement has not been established. Further it is uncertain if, and under what circumstances, shorter recording times are sufficient for a conclusive diagnosis.
View Article and Find Full Text PDF[This retracts the article DOI: 10.1016/j.jscai.
View Article and Find Full Text PDFArticle Synopsis
- Despite progress in recognizing and diagnosing spontaneous coronary artery dissection (SCAD) in the last decade, there is still limited understanding of its mechanisms, contributing factors, and effective treatments.
- The text highlights research gaps in SCAD and suggests strategies like patient advocacy, independent registries, and specialized centers to improve clinical care and research outcomes.
- Additionally, it presents a patient-centered clinical care and research framework developed by the SCAD Alliance and International SCAD registry as a model to enhance understanding and management of this condition.
Article Synopsis
- In early-stage triple-negative breast cancer (TNBC), high glucocorticoid receptor (GR) expression is linked to poor outcomes, potentially due to an immunosuppressed tumor microenvironment.
- A study of 47 patients showed that high GR expression correlated with increased levels of immunosuppressive FOXP3+ regulatory T cells and BATF3+ immune cells, but not significantly with CD8+ T cell infiltration.
- The findings suggest that high GR expression may contribute to a more immunosuppressed state in TNBC, which could explain worse prognoses for patients with GR-positive tumors.
Purpose: Advanced urothelial cancer generally has high mortality despite modern anti-PD-1/L1 antibody-based combinations. Augmenting checkpoint inhibitor-mediated immune responses with lymphocyte growth factors may improve outcomes. We conducted a randomized phase II study (CITN-14) in 47 patients to explore whether human recombinant IL-7 (CYT107) could be safely combined with PD-L1 inhibition to enhance responses.
View Article and Find Full Text PDF